An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Completed · Phase 3

Conditions studied: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder

In brief

The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.

Key facts

Study ID
NCT02003144
Run by
Alexion Pharmaceuticals, Inc.
People needed
119
Starts
2015-01-12
Expected to finish
2021-07-12
Last updated by the study team
2022-08-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.